Table 2.
AutoAbs individual predictive performance (n=392)
| (A) AutoAbs status | ||||||
|
Univariate
p value |
OR (95% CI) |
AUC
(95% CI) |
SEN/SPE
(95% CI) |
PPV/NPV
(95% CI) |
||
| ACPA 29 missing |
<0.0001 | 10.95 (6.20 to 19.35) |
0.748 (0.699 to 0.798) | 86% (79 to 92) 62% (59 to 67) |
52% (48 to 56) 90% (86 to 93) |
|
| RF eleven missing |
<0.0001 | 4.80 (3.03 to 7.57) |
0.687 (0.621 to 0.734) | 68% (60 to 75) 68% (62 to 73) |
51% (45 to 55) 81% (77 to 85) |
|
| anti-CarP 20 missing |
<0.0001 | 4.54 (2.88 to 7.18) |
0.670 (0.610 to 0.730) | 55% (45 to 63) 74% (69 to 80) |
53% (46 to 59) 76% (63 to 72) |
|
| anti-native CII 71 cases |
0.111 | |||||
| anti-GLY-CII 71 cases |
0.075 | |||||
| (B) AutoAbs levels | ||||||
|
Univariate
p value |
OR (95% CI) | Cut-off (AU/mL) | AUC (95% CI) |
SEN/SPE
(95% CI) |
PPV/NPV
(95% CI) |
|
| ACPA 29 missing |
<0.0001 | 1.005 (1.004 to 1.006) | 150 | 0.770 (0.716 to 0.824) | 56% (46 to 66) 75% (70 to 80) |
43% (37 to 50) 84% (80 to 86) |
| RF eleven missing |
<0.0001 | 1.002 (1. to 1.003) | 60 | 0.702 (0.645 to 0.750) | 5% (1 to 8) 98% (95 to 99) |
54% (21 to 38) 67% (66 to 68) |
| Anti-CarP 20 missing |
<0.0001 | 1.001 (1.001 to 1.003) | 300 | 0.720 (0.666 to 0.775) | 26% (19 to 35) 95% (92 to 97) |
70% (57 to 80) 72% (67 to 75) |
| (C) Risk categories | ||||||
|
Univariate
p value |
OR (95% CI) | AUC (95% CI) |
SEN/SPE
(95% CI) |
PPV/NPV
(95% CI) |
||
| ACPA 29 missing |
<0.0001 | 6.230 (3.971 to 9.776) |
0.710 (0.649 to 0.766) | 61% (51 to 69) 80% (75 to 85) |
60% (53 to 66) 81% (77 to 84) |
|
| RF eleven missing |
<0.0001 | 4.020 (2.617 to 6.176) |
0.641 (0.579 to 0.702) | 52% (43 to 60) 78% (73 to 83) |
54% (47 to 61) 77% (74 to 80) |
|
| Anti-CarP 20 missing |
<0.0001 | 4.169 (2.695 to 6.449) |
0.675 (0.615 to 0.735) | 51% (42 to 59) 80% (75 to 85) |
57% (50 to 63) 76% (73 to 79) |
|
ACPA, anticitrullinated protein antibody; AUC, area under the curve; PPV/NPV, positive and negative predictive value; RF, rheumatoid factor; SEN/SPE, sensitivity/specificity.